Why Dermatologists Get Sued: The Melanoma You Didn't Biopsy and the Laser Burn

By John Mahoney · June 2026 · 8 min read

Dermatology is one of the safest specialties to practice and one of the trickiest to litigate, because its risk is split down the middle. Most dermatology claims are cosmetic and procedural — laser burns, scarring, pigment changes — that are common but pay modestly. A much smaller group of claims is diagnostic — a missed melanoma or skin cancer — and those carry the highest payouts in the specialty by a wide margin. An attorney who treats every dermatology intake the same way will overvalue the cosmetic files and underestimate the rare diagnostic one. This guide explains where dermatology liability actually lives, the cannot-miss failures behind it, and what separates a strong case from a weak one — for plaintiff and defense med-mal attorneys.

Disclaimer: This article is for informational purposes only and does not constitute legal advice. The figures below draw on closed-claims and insurer datasets that span different eras and definitions; treat them as directional, verify against the controlling jurisdiction, and value any individual case on its own record.

The Frequency-and-Severity Reality

By frequency, dermatology is a low-risk specialty. In the Jena physician-malpractice analysis it carried roughly a 5% annual claim frequency against an all-specialty average near 7.4%, and in one of the largest closed-claims datasets dermatologists accounted for only about 1.2% of all closed claims, ranking near the bottom of the specialties despite making up a larger share of physicians. Cumulative career risk is still meaningful — most low-risk-specialty physicians face a claim by age 65 — but the annual exposure is among the lowest in medicine.

Severity is low-to-medium overall, with one sharp exception. Reported mean indemnity for dermatology has been among the lowest of the specialties (on the order of $118,000 in one analysis), average paid recovery ran below the all-specialty figure, and the largest single dermatology payout was a fraction of those seen elsewhere. Only about a quarter of closed claims resulted in any payment, and trial verdicts favored defendants by a wide margin. The exception that matters: missed-melanoma and skin-cancer diagnostic claims carry disproportionately high payouts — the costliest dermatology allegation type — and plaintiff-favorable laser suits also run above the dermatology average. The screening lesson is that two valuation models live inside this one specialty, and you must route every intake to the right one immediately.

The Dominant Allegation Types

Dermatology claims cluster into a procedural group and a diagnostic group, plus a consent thread that runs through both:

• Improper performance of a procedure — the single largest category, reported around 28% of closed claims, driven by elective and cosmetic procedures, surgical excisions, laser, Mohs, and biopsy technique.
• Diagnostic error / misdiagnosis or delayed diagnosis — reported around 18% of claims by count, but the highest total payout of any category. This is the small group of cases that drives the specialty's biggest dollars.
• Improper management / unexpected harm — in some recent litigation analyses, "unexpected harm" was the single largest driver, with diagnostic error close behind.
• Lack of informed consent / failure to communicate risks — central to cosmetic and laser claims.
• Medication errors — reported around 7%, involving agents such as isotretinoin, methotrexate, biologics, and steroid complications.

The structural point: by count, dermatology is a procedural specialty, but by dollars, the diagnostic claims dominate. Any intake should be triaged first on which side of that line it sits, because the merit analysis, the experts, and the damages are entirely different.

The Cannot-Miss Conditions and Failures

The conditions and failures that drive dermatology litigation are:

• Malignant melanoma — missed, delayed, or misread. This is the highest-severity exposure. In closed-claims data a large share of these are false-negative diagnoses, and melanoma is a leading misdiagnosed cancer in pathology claims as well. The recurring failure is a suspicious pigmented lesion that was not biopsied, or a biopsy result that was not followed up.
• Non-melanoma skin cancer (basal and squamous cell) — failure or delay to diagnose, a substantial claim and indemnity category.
• Dyschromia / pigmentary change — the most frequent adverse outcome by count, largely cosmetic and laser-related.
• Burns, scarring, and disfigurement from laser and energy devices — laser hair removal and skin rejuvenation dominate this group, and these suits run above the dermatology average in payout.
• Procedural complications — improper excision or biopsy, Mohs and cosmetic-surgery outcomes, and chemical peel, filler, or Botox injury, including nerve injury.

For the diagnostic side, the single most actionable screening question is the closed-loop question: was a suspicious lesion biopsied, and was the pathology result tracked, reported, and acted on? A melanoma claim very often turns on a result-notification or recall failure rather than a misread under the microscope. For the procedural side, the decisive question is who performed the procedure and whether the consent matched the realized harm.

The Contributing Factors That Drive Payouts

Across dermatology closed claims, the recurring contributing factors are:

• Technical skill / improper performance of a procedure — the single most common error category, around 28% of claims, with elective cosmetic procedures driving most paid claims.
• Clinical judgment / diagnostic process — the costliest factor: misread biopsies, failure to biopsy a suspicious lesion, and failure to track or follow up pathology results, which drive the high-severity melanoma and skin-cancer claims.
• Communication and informed consent — failure to convey procedure risks, medication side effects (such as isotretinoin), and unrealistic cosmetic expectations; "unexpected harm" dominated the recent litigation set, which is largely an expectations-and-consent problem.
• Supervision and delegation to non-physician operators — a distinctive dermatology amplifier. In laser-surgery litigation a large majority of cases — reported around 71% — involved non-physician operators, reflecting inadequate training or supervision.
• Documentation — incomplete records of consent, lesion descriptions, clinical photographs, and result-notification follow-up that weaken the defense.

Two of these are dermatology-specific levers. The first is the non-physician-operator amplifier: when a laser or energy device was operated by a delegate, the supervision question raises the expected-payment weighting and reframes the case around training and credentialing. The second is the result-notification record: in a missed-melanoma case, the line between a defensible file and a paid claim is often whether the chart shows the biopsy result was reported to the patient and acted on. Documentation rarely creates liability here, but it consistently decides whether a claim is paid.

Strong Case vs. Weak Case in Dermatology

The same factors grade the file, and the framing is useful to both sides.

What makes a dermatology case strong (plaintiff) / dangerous (defense)

• A suspicious pigmented lesion that was photographed or noted but never biopsied, or a melanoma biopsy result that was never reported to the patient — a clean closed-loop failure.
• A melanoma diagnosed at a stage where earlier action carried a materially better prognosis, supporting a strong loss-of-chance causation theory.
• A laser or energy-device injury performed by an inadequately supervised non-physician operator, with thin documentation of settings and skin-type assessment.
• A cosmetic-procedure harm with absent or generic informed consent that did not match the realized outcome.

What makes a dermatology case weak (plaintiff) / defensible (defense)

• A documented biopsy of the lesion with timely, recorded result-notification and appropriate management — the closed loop intact.
• A cosmetic outcome that was a disclosed, known risk with documented informed consent and realistic-outcome counseling, framing the harm as an accepted risk rather than negligence.
• A patient whose record shows declined biopsy, missed follow-up, or non-adherence that drove the delay.
• A procedure performed and supervised to credentialing standards with documented device settings, photographs, and consent.

Dermatology rewards a fast triage. On the diagnostic side, the case lives or dies on the closed loop and the loss-of-chance causation chain for the melanoma. On the procedural side, it turns on consent, expectation management, and — uniquely — who actually held the device and how they were supervised. Whichever side you are on, grading the file means matching the right model to the right claim and pressure-testing the expert who will carry it.

Bottom Line

Dermatologists get sued rarely, and most of the claims that come are cosmetic, procedural, and modest in value. But the specialty hides a sharp severity spike: missed-melanoma and skin-cancer diagnostic claims carry the highest payouts in dermatology, and laser injuries — frequently tied to non-physician operators — drive a disproportionate share of the litigation. The cannot-miss facts are the un-biopsied suspicious lesion, the un-reported pathology result, the unsupervised laser operator, and the consent that did not match the harm. Whether you are screening these cases for the plaintiff or defending them, triage first to the right model — diagnostic or procedural — and grade the file on the closed loop, the supervision record, and the documented consent, not on the visible injury alone.

Questions? Contact us at [email protected] or (856) 979-6525

🔎 Screening a case in a different specialty? Browse all 70 specialty malpractice-risk guides in one place — Why Doctors Get Sued: Malpractice Risk by Specialty →